Reactions 385 - 25 Jan 1992

Antineoplastics

T cell mutations: incidence studyConcern over the risk of secondary malignancies after

treatment of breast cancer led to a study of the incidence of Tlymphocyte mutations in 48 women who received variouspostoperative therapies.

Overall, a significant increase in the frequency of mutationsfrom baseline was observed 6 months after therapy. Thisfrequency gradually decreased and approached baseline 2years after therapy. Tamoxifen, radiotherapy or lack ofpostoperative treatment could not be linked with thefrequency of mutations. However, antineoplastic therapy wassignificantly correlated with increased mutation frequency.

A better understanding of the risk factors for secondarymalignancy could reduce the frequency of this event withoutreducing initial response ratesBranda RF, et al. Factors influencing mutation at the hprt locus in T-lymphocytes:women treated for breast cancer. Cancer Research 51: 6603-6607, 15 Dec 1991 -USA 800114369

1

Reactions 25 Jan 1992 No. 3850114-9954/10/0385-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved